SNOA — Sonoma Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $4.88m
- -$0.27m
- $14.29m
- 48
- 63
- 70
- 63
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.11 | ||
| Price to Tang. Book | 1.11 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -38.66% | ||
| Return on Equity | -65.55% | ||
| Operating Margin | -25.97% | ||
Financial Summary
| Year End 31st Mar | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 18.63 | 12.63 | 13.27 | 12.73 | 14.29 | 17.23 | 21.47 | -4.44% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.
Directors
- Amy Trombly CEO (54)
- Jerry Dvonch CFO (52)
- Bruce Thornton COO (57)
- Jerry Mclaughlin LED (73)
- Jay Birnbaum IND (76)
- Philippe Weigerstorfer IND (61)
- Last Annual
- March 31st, 2025
- Last Interim
- March 31st, 2025
- Incorporated
- November 20th, 2006
- Public Since
- January 26th, 2007
- No. of Shareholders
- 61
- No. of Employees
- 168
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,642,765
- Address
- 5445 CONESTOGA COURT, SUITE 150, BOULDER, 80301
- Web
- https://sonomapharma.com/
- Phone
- +1 6172430050
- Auditors
- Frazier & Deeter, LLC
Upcoming Events for SNOA
Sonoma Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2026 Sonoma Pharmaceuticals Inc Earnings Release
Similar to SNOA
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
What is the Sonoma Pharmaceuticals share price?
As of Today at 23:21 UTC, shares in Sonoma Pharmaceuticals are trading at $2.97. This share price information is delayed by 15 minutes.
How has the Sonoma Pharmaceuticals share price performed this year?
Shares in Sonoma Pharmaceuticals last closed at $2.97 and the price had moved by -46.7% over the past 365 days. In terms of relative price strength the Sonoma Pharmaceuticals share price has underperformed the S&P500 Index by -52.35% over the past year.
What are the analyst and broker recommendations for Sonoma Pharmaceuticals?
The overall consensus recommendation for Sonoma Pharmaceuticals is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sonoma Pharmaceuticals dividend yield?
Sonoma Pharmaceuticals does not currently pay a dividend.
Does Sonoma Pharmaceuticals pay a dividend?
Sonoma Pharmaceuticals does not currently pay a dividend.
When does Sonoma Pharmaceuticals next pay dividends?
Sonoma Pharmaceuticals does not currently pay a dividend.
How do I buy Sonoma Pharmaceuticals shares?
To buy shares in Sonoma Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sonoma Pharmaceuticals?
As of the previous close price of $2.97, shares in Sonoma Pharmaceuticals had a market capitalisation of $4.88m.
Where are Sonoma Pharmaceuticals shares listed?
Here are the trading details for Sonoma Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SNOA
What kind of share is Sonoma Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Sonoma Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sonoma Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Sonoma Pharmaceuticals is $14.80. That is 398.32% above the last closing price of $2.97.
Analysts covering Sonoma Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.32 for the next financial year.
Find out moreWhat is the trend in the Sonoma Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sonoma Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +7.95%.
As of the last closing price of $2.97, shares in Sonoma Pharmaceuticals were trading +2.67% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sonoma Pharmaceuticals PE Ratio?
The Sonoma Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.97.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sonoma Pharmaceuticals?
Sonoma Pharmaceuticals' management team is headed by:
- Amy Trombly - CEO
- Jerry Dvonch - CFO
- Bruce Thornton - COO
- Jerry Mclaughlin - LED
- Jay Birnbaum - IND
- Philippe Weigerstorfer - IND